IGC Pharma Inc. logo

IGC Pharma Inc. (IGS1)

Market Closed
24 Jul, 20:00
XSTU XSTU
0. 31
-0
-1.26%
- Market Cap
- P/E Ratio
0.08% Div Yield
0 Volume
-0.22 Eps
0.32
Previous Close
Day Range
0.31 0.32
Year Range
0.22 0.46
Want to track IGS1 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 11 days

Summary

IGS1 closed yesterday lower at €0.31, a decrease of 1.26% from Wednesday's close, completing a monthly increase of 26.61% or €0.07. Over the past 12 months, IGS1 stock gained 1.29%.
IGS1 is not paying dividends to its shareholders.
The last earnings report, released on Jun 30, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.01%, based on the last three reports. The next scheduled earnings report is due on Aug 05, 2025.
IGC Pharma Inc. has completed 1 stock splits, with the recent split occurring on Apr 19, 2013.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on AMEX (USD).

IGS1 Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
IGC Pharma, Inc. (IGC) Reports Q4 Loss, Beats Revenue Estimates

IGC Pharma, Inc. (IGC) Reports Q4 Loss, Beats Revenue Estimates

IGC Pharma, Inc. (IGC) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.04 per share a year ago.

Zacks | 4 weeks ago
IGC Pharma, Inc. (IGC) Reports Q3 Loss, Tops Revenue Estimates

IGC Pharma, Inc. (IGC) Reports Q3 Loss, Tops Revenue Estimates

IGC Pharma, Inc. (IGC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.09 per share a year ago.

Zacks | 5 months ago
IGC Pharma, Inc. (IGC) Upgraded to Strong Buy: What Does It Mean for the Stock?

IGC Pharma, Inc. (IGC) Upgraded to Strong Buy: What Does It Mean for the Stock?

IGC Pharma, Inc. (IGC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks | 5 months ago

IGC Pharma Inc. Dividends

IGS1 is not paying dividends to its shareholders.

IGC Pharma Inc. Earnings

14 Aug 2025 (In 2 weeks) Date
-
Cons. EPS
-
EPS
5 Aug 2025 (In 1 week) Date
-
Cons. EPS
-
EPS
30 Jun 2025 Date
-
Cons. EPS
-
EPS
24 Jun 2025 Date
-
Cons. EPS
-
EPS
18 Jun 2025 Date
-
Cons. EPS
-
EPS
IGS1 is not paying dividends to its shareholders.
14 Aug 2025 (In 2 weeks) Date
-
Cons. EPS
-
EPS
5 Aug 2025 (In 1 week) Date
-
Cons. EPS
-
EPS
30 Jun 2025 Date
-
Cons. EPS
-
EPS
24 Jun 2025 Date
-
Cons. EPS
-
EPS
18 Jun 2025 Date
-
Cons. EPS
-
EPS

IGC Pharma Inc. (IGS1) FAQ

What is the stock price today?

The current price is €0.31.

On which exchange is it traded?

IGC Pharma Inc. is listed on AMEX.

What is its stock symbol?

The ticker symbol is IGS1.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.08%.

What is its market cap?

As of today, no market cap data is available.

When is the next earnings date?

The next earnings report will release on Aug 05, 2025.

Has IGC Pharma Inc. ever had a stock split?

IGC Pharma Inc. had 1 splits and the recent split was on Apr 19, 2013.

IGC Pharma Inc. Profile

Conglomerates Industry
Industrials Sector
Ram Mukunda CEO
XSTU Exchange
US45408X3089 ISIN
US Country
67 Employees
- Last Dividend
19 Apr 2013 Last Split
13 Apr 2006 IPO Date

Overview

IGC Pharma, Inc., initially known as India Globalization Capital, Inc., is a transformative clinical stage biotechnology firm that has carved out a niche in developing innovative cannabinoid-based treatments. With its rebranding in March 2023, IGC Pharma has sharpened its focus on addressing a variety of diseases and conditions that significantly impact human health, such as Alzheimer's disease, dysmenorrhea, premenstrual syndrome (PMS), and chronic pain. Founded in 2005 and based in Potomac, Maryland, the company leverages cutting-edge science to pioneer treatments aimed at improving the quality of life for patients across these challenging conditions.

Products and Services

IGC Pharma, Inc. is at the forefront of research and development in the realm of cannabinoid-based therapeutics, with a robust pipeline that includes investigational drug assets and wellness brands.

  • IGC-AD1
  • This investigational drug is currently in a Phase 2B clinical trial and is designed as a potential treatment for agitation in dementia due to Alzheimer's disease. IGC-AD1 represents IGC Pharma’s commitment to addressing the complexities of Alzheimer’s, focusing on one of its most distressing manifestations.

  • TGR-63
  • Still in the pre-clinical development stage, TGR-63 is another promising investigational asset targeting Alzheimer's disease. This drug is part of IGC Pharma's strategic efforts to diversify its portfolio in the fight against neurodegenerative diseases, showcasing the company's dedication to groundbreaking research.

  • Holief
  • A wellness brand marketed by IGC Pharma, Holief targets women experiencing PMS and menstrual cramps. Emphasizing natural, cannabinoid-based relief, Holief stands as a testament to the company’s initiative to not only focus on clinical therapeutics but also offer wellness products that aid in everyday discomforts associated with menstrual health.

Contact Information

Address: 10224 Falls Road
Phone: 301 983 0998